Trial readouts

What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.

Trial readouts

TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks

Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.

30 May 2026 · PeptideMethods Editorial Team · 6 min read